News
Disordered eating liked to pelvic floor disorders in middle-aged women
Eating behaviour is associated with symptoms of pelvic floor disorders in middle-aged women, new research has found.
For example, higher consumption of highly processed ready-made foods and fast food increased the risk for experiencing symptoms of stress and urgency urinary incontinence.
Higher consumption of fruits and an overall higher quality diet decreased the risk for stress urinary incontinence.
The prevalence of pelvic floor disorders increases as women approach their menopausal years.
Estrogen deprivation during menopause, natural aging, reproductive history, and factors increasing intra-abdominal pressure may lead to structural and functional failure in the pelvic floor.
In addition, lifestyle choices such as quality of nutrition and eating behaviour may have a significant effect on the mechanisms of pelvic floor disorders.
Doctoral researcher Mari Kuutti is from the Faculty of Sport and Health Sciences of the University of Jyväskylä.
Kuutti said: “Eating behaviour has been minimally studied as a potential risk factor for pelvic floor disorders.
“We studied how disordered eating can affect the onset of the symptoms.”
Disordered eating includes overeating, restrictive eating as well as alternating between the two behaviours.
Kuutti said: “We found that women who reported disordered eating were more likely to experience the symptoms of pelvic floor disorders than were women who had reported normal eating,”
The disorders studied were stress urinary incontinence, urgency urinary incontinence, fecal incontinence, and constipation and defecation difficulties.
Over half of the participants of the study had symptoms of pelvic floor disorders. Most common was stress urinary incontinence.
The study revealed that eating behaviour and consuming some dietary items were associated with onset of the symptoms of pelvic floor disorders.
Kuutti said: “We studied the potential negative and positive associations of common Finnish food items with the symptoms of pelvic floor disorders.
“For example, higher consumption of highly processed ready-made foods and fast food increased the risk for experiencing the symptoms of stress and urgency urinary incontinence.
Higher consumption of fruits and overall higher quality diet decreased the risk for stress urinary incontinence.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






